Kalaris Therapeutics (KLRS) Depreciation & Amortization (CF) (2020 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Depreciation & Amortization (CF) of $10000.0 for Q1 2026, little changed quarter-over-quarter from $10000.0 in Q4 2025.
Kalaris Therapeutics (KLRS) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Kalaris Therapeutics' Depreciation & Amortization (CF) history runs 6 years deep, the most recent figure standing at $10000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) changed N/A year-over-year to $10000.0; the TTM figure through Mar 2026 stood at $20000.0 (changed N/A YoY), while the FY2025 annual figure was $13000.0, changed N/A from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $10000.0, roughly flat from $10000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $466000.0 in Q1 2022, with the low at $10000.0 in Q4 2025.
- The 4-year median for Depreciation & Amortization (CF) is $86000.0 (2022), against an average of $114100.0.
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) soared 2488.89% in 2022, then plunged 81.55% in 2023.
- Kalaris Therapeutics' Depreciation & Amortization (CF) stood at $86000.0 in 2022, then surged by 63.95% to $141000.0 in 2023, then tumbled by 92.91% to $10000.0 in 2025, then changed by 0.0% to $10000.0 in 2026.
- Business Quant data shows KLRS's Depreciation & Amortization (CF) at $10000.0 in Q1 2026, $10000.0 in Q4 2025, and $141000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kalaris Therapeutics | 100.19 Mn | 100.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10,000.00 |
| Jun 30, 2026 | 10,000.00 |
| Mar 31, 2026 | 10,000.00 |
| Mar 31, 2026 | 10,000.00 |
| Dec 31, 2025 | 10,000.00 |
| Dec 31, 2025 | 10,000.00 |
| Dec 31, 2023 | 141,000.00 |
| Dec 31, 2023 | 141,000.00 |
| Sep 30, 2023 | 86,000.00 |
| Sep 30, 2023 | 86,000.00 |
| Jun 30, 2023 | 85,000.00 |
| Jun 30, 2023 | 85,000.00 |
| Mar 31, 2023 | 86,000.00 |
| Mar 31, 2023 | 86,000.00 |
| Dec 31, 2022 | 86,000.00 |
| Dec 31, 2022 | 86,000.00 |
| Sep 30, 2022 | 85,000.00 |
| Sep 30, 2022 | 85,000.00 |
| Jun 30, 2022 | 86,000.00 |
| Jun 30, 2022 | 86,000.00 |